Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
NCT07282652Phase 1Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RAG-18 in Duchenne muscular dystrophy (DMD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence and Severity of Adverse Events and Serious Adverse Events at Day 169. Started Dec 2025; status: active, not recruiting.
02
Drugs
RAG-18
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07282652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282652.